TY - JOUR
T1 - Refractory T-cell/histiocyte-rich large B-cell lymphoma in a patient with ataxia–telangiectasia caused by novel compound heterozygous variants in ATM
AU - Sato, Daichi
AU - Moriya, Kunihiko
AU - Nakano, Tomohiro
AU - Miyagawa, Chihiro
AU - Katayama, Saori
AU - Niizuma, Hidetaka
AU - Sasahara, Yoji
AU - Kure, Shigeo
N1 - Funding Information:
We thank the patient and her parents for participating in this study. We thank all of our colleagues in the Department of Pediatrics who have been involved in the patient’s care and research. Kunihiko Moriya was supported by grant from the Japanese Ministry of Health, Labour and Welfare of Japan (Grant Number 19K23819).
Publisher Copyright:
© 2021, Japanese Society of Hematology.
PY - 2021/12
Y1 - 2021/12
N2 - Ataxia–telangiectasia (A–T) is an autosomal recessive chromosomal breakage syndrome caused by mutation of the ATM (A–T mutated) gene, which encodes a protein kinase that has a major role in the cellular response to DNA damage. Approximately, 10% of A–T patients develop lymphoid malignancies. Deaths caused by extreme sensitivity to chemotherapy for malignancy have been reported, and cancer treatment in A–T is extraordinarily difficult, needing careful monitoring and individualized protocols. We report the case of a 12-year-old girl with A–T diagnosed at the age of 3 in association with IgA deficiency and recurrent pulmonary infections. Sanger sequencing revealed compound heterozygosity of the ATM gene, which bore two novel mutations. At the age of 12, she developed stage IV T-cell/histiocyte-rich large B-cell lymphoma. The tumor was resistant to chemotherapy, and she unfortunately died of cardiac insufficiency and multiple organ failure induced by rapid progression of the disease. The treatment approach for children with A–T and advanced-stage B-non-Hodgkin lymphoma must be refined.
AB - Ataxia–telangiectasia (A–T) is an autosomal recessive chromosomal breakage syndrome caused by mutation of the ATM (A–T mutated) gene, which encodes a protein kinase that has a major role in the cellular response to DNA damage. Approximately, 10% of A–T patients develop lymphoid malignancies. Deaths caused by extreme sensitivity to chemotherapy for malignancy have been reported, and cancer treatment in A–T is extraordinarily difficult, needing careful monitoring and individualized protocols. We report the case of a 12-year-old girl with A–T diagnosed at the age of 3 in association with IgA deficiency and recurrent pulmonary infections. Sanger sequencing revealed compound heterozygosity of the ATM gene, which bore two novel mutations. At the age of 12, she developed stage IV T-cell/histiocyte-rich large B-cell lymphoma. The tumor was resistant to chemotherapy, and she unfortunately died of cardiac insufficiency and multiple organ failure induced by rapid progression of the disease. The treatment approach for children with A–T and advanced-stage B-non-Hodgkin lymphoma must be refined.
KW - Ataxia–telangiectasia
KW - Chemotherapy
KW - T-cell/histiocyte-rich large B-cell lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85113730766&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113730766&partnerID=8YFLogxK
U2 - 10.1007/s12185-021-03203-w
DO - 10.1007/s12185-021-03203-w
M3 - Article
C2 - 34424493
AN - SCOPUS:85113730766
SN - 0925-5710
VL - 114
SP - 735
EP - 741
JO - International Journal of Hematology
JF - International Journal of Hematology
IS - 6
ER -